BioengineeringbioRxiv
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
E. Zah, E. Nam, V. Bhuvan…·Y. Y. Chen
This study develops BCMA/CS1 bispecific CAR-T cells that effectively target heterogeneous multiple myeloma, showing improved activity and durable tumor-free survival compared to single-target CAR-T cells.
DOI 10.1038/s41467-020-16160-5